Celldex Therapeutics Inc Revenue Growth Rates (CLDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Celldex Therapeutics inc   (NASDAQ: CLDX)
 

CLDX's Revenue Growth by Quarter and Year

Celldex Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CLDX/growth
https://api.csimarket.com/api/v1/companies/CLDX/fundamentals
https://api.csimarket.com/api/v1/companies/CLDX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
CLDX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.02
1st Quarter March 0.02
FY 0.04

CLDXs Annual Revenue
Celldex Therapeutics Inc 's Revenue in the fiscal year 2025 $ 1.55 millions
Celldex Therapeutics Inc 's Revenue in the fiscal year 2024 $ 7.02 millions
Celldex Therapeutics Inc 's Revenue in the fiscal year 2023 $ 6.88 millions
Celldex Therapeutics Inc 's Revenue in the fiscal year 2022 $ 2.36 millions
Celldex Therapeutics Inc 's Revenue in the fiscal year 2021 $ 4.65 millions




CLDX Revenue third quarter 2026 Y/Y Growth Comment
Celldex Therapeutics inc in the third quarter 2026 recorded of $ 0.00 millions.

Looking into third quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Revenue growth. While Celldex Therapeutics Inc ' s Revenue no change of 0% ranks overall at the positon no. 3934 in the third quarter 2026.


CLDX Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -97.26 %
1st Quarter March -97.14 %
FY   -

Financial Statements
Celldex Therapeutics Inc 's third quarter 2026 Revenue $ 0.00 millions CLDX's Income Statement
Celldex Therapeutics Inc 's third quarter 2025 Revenue $ 0.00 millions Quarterly CLDX's Income Statement


CLDX Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 0 %
1st Quarter March -83.33 %
FY (Year on Year)   -


Back to CLDX Growth rate Comparisons >> Back to CLDX Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #574
Overall #3934

Revenue Y/Y Growth Statistics
High Average Low
1374.58 % 76.27 % -100 %
(Sep 30 2023)   (Jun 30 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #574
Overall #3934
Revenue Y/Y Growth Statistics
High Average Low
1374.58 % 76.27 % -100 %
(Sep 30 2023)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Celldex Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1501.28 % 74.78 % -100 %
(Jun 30 2024)  


CLDX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Celldex Therapeutics inc come out even worse considering the 0.02 millions a quarter before.

Within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Celldex Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3879.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #578
Overall #3879
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #13
Healthcare Sector #578
Overall #3879
Revenue Q/Q Growth Statistics
High Average Low
1501.28 % 74.78 % -100 %
(Jun 30 2024)  


CLDX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Celldex Therapeutics inc come out even worse considering the 0.02 millions a quarter before.

Within In Vitro & In Vivo Diagnostic Substances industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Celldex Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3879.


Celldex Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking # 3520
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking # 3460


Cumulative Revenue growth Comment
In the Sep 30 2026 period, Celldex Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 538 to 3520.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 11
Healthcare Sector # 474
Overall # 3520

Revenue TTM Y/Y Growth Statistics
High Average Low
305.29 %
 26.81 %
-90.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 460
S&P 500 # 3460
Cumulative Revenue growth Comment
In the Sep 30 2026 period, Celldex Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 473 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 538 to 3520.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 11
Healthcare Sector # 474
Overall # 3520

Revenue TTM Y/Y Growth Statistics
High Average Low
305.29 %
26.81 %
-90.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 460
S&P 500 # 3460




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CLDX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Nuwellis Inc -0.23%$ -0.226 millions
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions


About Celldex Therapeutics Inc Revenue Growth Rates (CLDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Celldex Therapeutics Inc (CIK 744218).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-123322
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Celldex Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.